ReviewStem cells international2026
Stem Cell Models for Elucidating Cellular Mechanisms of Substance Use Disorders and Advancing Addiction Pharmacology.
Review in Stem cells international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Stem Cell Models for Elucidating Cellular Mechanisms of Substance Use Disorders and Advancing Addiction Pharmacology.Stem cells international · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Substance use disorders (SUDs) impose major global morbidity and mortality, yet the cellular mechanisms linking genetic risk to neural vulnerability, disrupted neurodevelopment, and drug-induced neuroadaptations remain poorly understood. Human pluripotent stem cell (hPSC) technologies, including embryonic and induced pluripotent stem cell (ESC/iPSC)-derived neurons, three-dimensional (3D) brain organoids, and organoid-on-a-chip platforms, provide scalable, human-relevant models to address this gap. ESC/iPSC-derived neuronal cultures enable interrogation of genetic and epigenetic determinants of drug susceptibility and response; cerebral organoids recapitulate tissue architecture and emergent network dynamics; and microfluidic organoid-on-a-chip systems facilitate maturation, enhance reproducibility, and enable controlled exposure paradigms. In this review, we synthesize recent stem cell-based studies of alcohol, opioid, and stimulant exposure, highlighting insights into neurodevelopmental disruption, synaptic and signaling alterations, neuroinflammation, and network-level dysfunction. We critically evaluate limitations of stem cell-based studies, including ethical concerns, inter- and intra-line variability, incomplete cellular maturation, and difficulties in modeling complex circuitry and comorbid conditions. We propose strategies to enhance translational relevance, including standardized differentiation protocols, addition of patient-derived cells and vascular and immune components, and integration of multi-omics approaches (transcriptomics, epigenomics, and proteomics) with functional readouts to map molecular pathways underlying drug vulnerability and resilience. Finally, we outline the therapeutic and precision-medicine potential of stem cell platforms for target discovery, predictive toxicology, and individualized treatment modeling. Despite remaining challenges, stem cell-based approaches offer a powerful and increasingly tractable path from genetic association to mechanistic insight and therapeutic innovation in addiction research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.